FDA to pull common but ineffective cold medicine from market

The Food and Drug Administration announced Wednesday that it would activity to propulsion a widely utilized ingredient successful cough and acold medicines from nan market, aft nan agency's scientists concluded that nan oral type of nan supplier is ineffective arsenic a nasal decongestant.

The FDA's connection comes much than a twelvemonth aft nan agency's extracurricular advisers voted against continued usage of nan ingredient, called oral phenylephrine, citing concerns pinch nan first information utilized to support its support and caller information questioning its effectiveness.

A number of communal over-the-counter nasal decongestants person relied connected phenylephrine unsocial aliases successful operation pinch different ingredients for years, including immoderate acold and cough versions of Advil, NyQuil, Sudafed, Robitussin, Tylenol and Theraflu.

"Based connected our reappraisal of disposable data, and accordant pinch nan proposal of nan advisory committee, we are taking this adjacent measurement successful nan process to propose removing oral phenylephrine because it is not effective arsenic a nasal decongestant," Dr. Patrizia Cavazzoni, head of nan FDA's Center for Drug Evaluation and Research, said successful a news release.

The agency's projected order would region oral phenylephrine from nan "monograph" of ingredients that drugmakers are allowed to usage successful cough and acold medicines which are sold connected shop shelves without a prescription.

The nationalist has until May 7 adjacent twelvemonth to measurement successful connected nan proposal. After that remark period, if nan FDA decides to finalize its connection to revoke oral phenylephrine's position arsenic "generally recognized arsenic safe and effective," over-the-counter drugmakers would beryllium forced to extremity utilizing nan ingredient.

"The FDA would supply manufacturers pinch due clip to either reformulate narcotics containing oral phenylephrine aliases region specified narcotics from nan market," nan agency said successful its release.

The Consumer Healthcare Products Association said Thursday it was "disappointed" successful nan FDA's proposal. The manufacture waste and acquisition group renewed its declare that nary changes "are warranted" for oral phenylephrine and cited erstwhile FDA and advisory committee decisions that did not telephone for pulling nan ingredient.

"PE should stay an disposable action for consumers, because Americans merit nan action to take nan safe and effective OTC medicines they for illustration and trust on," Scott Melville, CHPA's president and CEO, said successful a statement.

After nan FDA's advisory committee past year, drugstore chain CVS said it would pull any products connected its shelves that only contained nan product.

Spokespeople for drugmakers down nan brands did not instantly respond to requests for comment. 

The FDA's connection caps a push by drugstore professors astatine nan University of Florida who have urged nan agency for years to propulsion nan product, pointing to caller information showing phenylephrine did nary amended than a placebo erstwhile swallowed.

The latest information shows that only a mini fraction of phenylephrine is absorbed into nan assemblage erstwhile digested from a pill aliases syrup containing phenylephrine. This is different from different formulations for illustration nan inhaled nasal spray versions of nan drug, wherever larger percentages of nan supplier tin make it into nan bloodstream.

The researchers besides person questioned nan first studies that were tally to beryllium nan drug's effectiveness, though they admit that it is safe astatine presently approved levels.

"Let maine beryllium clear, oral phenylephrine is not a information risk," Hatton, a professor astatine nan University of Florida, told CBS News past year. "It conscionable doesn't work."

In a technological review published this week by nan FDA, nan agency's scientists concluded that past studies estimating that higher percentages of nan supplier could beryllium absorbed during digestion were "an overestimate and based connected outdated technology."

Less than 1% of nan supplier is absorbed into nan bloodstream aft being swallowed, they estimated. Far higher doses could "be needed to execute a clinically meaningful result which would raise important questions astir safety."

"Furthermore, location are nary objective information demonstrating that oral PE is effective arsenic a nasal decongestant astatine immoderate dosage," nan FDA's scientists wrote.

In:
• Food and Drug Administration